Wadzanai Samaneka
A5038527599- Pneumocystis jirovecii pneumonia detection and treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Tuberculosis Research and Epidemiology
- HIV Research and Treatment
- Pharmacological Effects and Toxicity Studies
- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Pregnancy and Medication Impact
- Hepatitis C virus research
- Cervical Cancer and HPV Research
- Mycobacterium research and diagnosis
- Hepatitis B Virus Studies
- Pneumonia and Respiratory Infections
- Reproductive Health and Contraception
- Antibiotic Resistance in Bacteria
- Genital Health and Disease
- Trace Elements in Health
- SARS-CoV-2 detection and testing
- Pharmacological Effects of Natural Compounds
- Clinical Laboratory Practices and Quality Control
- Folate and B Vitamins Research
- Selenium in Biological Systems
- Syphilis Diagnosis and Treatment
University of Zimbabwe
2016-2025
Parirenyatwa Hospital
2019-2025
University of Zimbabwe-University of California San Francisco
2014-2018
Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis.
PEARLS, a large scale trial of antiretroviral therapy (ART) for HIV (n = 1,571, 9 countries, 4 continents), found that once-daily protease inhibitor (PI) based regimen (ATV+DDI+FTC), but not non-nucleoside reverse transcriptase inhibitor/nucleoside (NNRTI/NRTI) (EFV+FTC/TDF), had inferior efficacy compared to standard care twice-daily NNRTI/NRTI (EFV+3TC/ZDV). The present study examined non-adherence in PEARLS.Outcomes: assessed by pill count and self-report, time treatment failure....
Background: Many HIV-infected individuals present with advanced HIV disease. These patients are at high risk of death after antiretroviral therapy (ART) initiation, but factors for in these unclear. Methods: We used data from a multisite randomized trial comparing empiric vs. preventive tuberculosis adults initiating ART CD4+ T-cell counts less than 50 cells/μl to evaluate within 48 weeks initiation. Cox proportional hazards models were fit characteristics baseline and 4 including the week...
Numerous micronutrients have immunomodulatory roles that may influence risk of tuberculosis (TB), but the association between baseline micronutrient deficiencies and incident TB after antiretroviral therapy (ART) initiation in HIV-infected individuals is not well characterized.We conducted a case-cohort study (n = 332) within randomized trial comparing 3 ART regimens 1571 HIV treatment-naive adults from 9 countries. A subcohort 30 patients was randomly selected each country 270). Cases 77;...
Mild-to-moderate AIDS-associated Kaposi sarcoma (KS) often responds to antiretroviral therapy (ART) alone; the role of chemotherapy is unclear. We assessed impact immediate vs as-needed oral etoposide (ET) among human immunodeficiency virus (HIV)-infected individuals with mild-to-moderate KS initiating ART.Chemotherapy-naive, HIV type 1-infected adults ART in Africa and South America were randomized (tenofovir/emtricitabine/efavirenz) alone (chemotherapy "as-needed" arm) plus up 8 cycles ET...
One month of daily rifapentine + isoniazid (1HP) is an effective, ultrashort option for tuberculosis prevention in people with human immunodeficiency virus (HIV). However, may decrease antiretroviral drug concentrations and increase the risk virologic failure. AIDS Clinical Trials Group A5372 evaluated effect 1HP on pharmacokinetics twice-daily dolutegravir.
Guidelines for limited-stage human immunodeficiency virus-associated Kaposi sarcoma (AIDS/KS) recommend antiretroviral therapy (ART) as initial treatment. However, many such individuals show worsening KS and require additional chemotherapy. Methods to identify patients are lacking.
In Advancing Clinical Therapeutics Globally protocol A5372, a pharmacokinetic study of dolutegravir with 1-month daily rifapentine/isoniazid, twice-daily offset the induction effects rifapentine on plasma trough concentrations (C ). Here, we characterize impact C UGT1A1 , AADAC and NAT2 polymorphisms that affect dolutegravir, rifapentine, isoniazid, respectively. People HIV receiving dolutegravir-based antiretroviral therapy an indication to treat latent tuberculosis underwent sampling...
A previous study demonstrated noninferior efficacy of 4-month rifapentine/moxifloxacin regimen for tuberculosis (TB) treatment compared with the standard regimen. We explored results among participants diabetes. Among 2,516 randomized participants, 181 (7.2%) had Of 166 diabetes in microbiologically eligible analysis group, 26.3% (15/57) unfavorable outcomes control regimen, 13.8% (8/58) and 29.4% (15/51) rifapentine The difference proportion between arms group was -12.5% (95% CI -27.0% to...
Abstract Background Tenofovir/lamivudine/dolutegravir (TLD) is widely prescribed worldwide. We report virologic and resistance outcomes for patients initiating or switching to TLD. Methods A prospective observational study was performed at 13 AIDS Clinical Trials Group (ACTG) sites in six PEPFAR-supported countries coincident with TLD rollout. This includes results from two groups: Gp1 were virally suppressed on NNRTI-based ART Gp2 ART-naïve initiation. The primary objective estimate the...
Background. Combination antiretroviral therapy (cART) reduces genital tract human immunodeficiency virus type 1 (HIV-1) load and the risk of sexual transmission, but little is known about efficacy cART for decreasing viral (GTVL) differences in sex or HIV-1 subtype.
A case-cohort analysis of human immunodeficiency virus (HIV)–infected individuals receiving antiretroviral therapy (ART) was performed within a multicountry randomized trial (PEARLS) to assess the prevalence persistently elevated C-reactive protein (CRP) levels, based on serial measurements CRP and their association with HIV clinical failure. level in plasma (defined as ≥ 5 mg/L at both baseline 24 weeks after ART initiation) observed 50 205 (24%). but not an only single time point...
Background. Anemia is a known risk factor for clinical failure following antiretroviral therapy (ART). Notably, anemia and inflammation are interrelated, recent studies have associated elevated C-reactive protein (CRP), an marker, with adverse human immunodeficiency virus (HIV) treatment outcomes, yet their joint effect not known. The objective of this study was to assess prevalence factors in HIV infection determine whether CRP jointly predict post-ART. Methods. A case-cohort (N = 470 [236...
Background Laboratory reference ranges used for clinical care and trials in various laboratories Zimbabwe were derived from textbooks research studies conducted more than ten years ago. Periodic verification of these is essential to track changes over time. The purpose this study was establish hematology chemistry laboratory using rigorous methods. Methods A community-based cross-sectional carried out Harare, Chitungwiza, Mutoko. multistage sampling technique used. Samples transported the...
Abstract Background Reproductive aging may contribute to cardiometabolic comorbid conditions. We integrated data on gynecologic history with levels of an ovarian reserve marker (anti-müllerian hormone [AMH)] interrogate reproductive patterns and associated factors among a subset cisgender women human immunodeficiency virus (WWH) enrolled in the REPRIEVE trial. Methods A total 1449 WWH were classified as premenopausal (n = 482) (menses within 12 months; AMH level ≥20 pg/mL; group 1), reduced...
A case-cohort study, within a multi-country trial of antiretroviral therapy (ART) efficacy (Prospective Evaluation Antiretrovirals in Resource Limited Settings (PEARLS)), was conducted to determine if pre-ART serum selenium deficiency is independently associated with human immunodeficiency virus (HIV) disease progression after ART initiation. Cases were HIV-1 infected adults either clinical failure (incident World Health Organization (WHO) stage 3, 4 or death by 96 weeks) virologic 24...
Tenofovir-lamivudine-dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen. An additional 50-mg dose of dolutegravir (TLD+50) required with rifampin-containing tuberculosis (TB) co-treatment. There are limited data on effectiveness TLD+50 in individuals TB/human immunodeficiency virus (HIV). We performed a prospective, observational cohort study at 12 sites Haiti, Kenya, Malawi, South Africa, Uganda, and Zimbabwe. Participants starting TLD TB treatment were...
Tenofovir disoproxil fumarate (TDF) has been associated with renal insufficiency. Co-administration boosted protease inhibitors, which increases its exposure, may further increase the risk of insufficiency.We compared incidence events among women taking TDF co-administered lopinavir/ritonavir (LPV/r) versus those co-administering nevirapine (NVP). Renal were defined as a confirmed drop in creatinine clearance serum grade 2 or higher, that leading to treatment modification.Overall, 741...
Abstract Background. We assessed immune activation after antiretroviral therapy (ART) initiation to understand clinical failure in diverse settings. Methods. performed a case-control study ACTG Prospective Evaluation of Antiretrovirals Resource-Limited Settings (PEARLS). Cases were defined as incident World Health Organization Stage 3 or 4 human immunodeficiency virus (HIV) disease death, analyzed from ART weeks 24 (ART24) 96. Controls randomly selected. Interleukin (IL)-6, interferon...
We evaluated health-related quality of life (QoL) in HIV infection participants with virologic failure (VF) on first-line antiretroviral therapy (ART) 9 resource-limited settings (RLS). ACTG SF-21 was completed by 512 at A5273 study entry; 8 domains assessed: general health perceptions (GHP), physical functioning (PF), role (RF), social (SF), cognitive (CF), pain (P), mental (MH), and energy/fatigue (E/F); each scored between 0 (worst) to 100 (best). Mean QoL scores ranged from 67 (GHP) 91...